RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 52.58B
Enterprise Value 32B
Trailing P/E N/A
Forward P/E 1-8.51
PEG Ratio (5 yr expected) 1-0.38
Price/Sales (ttm)36.71
Price/Book (mrq)3.15
Enterprise Value/Revenue 328.49
Enterprise Value/EBITDA 6-5.27

Trading Information

Stock Price History

Beta (3Y Monthly) 2.85
52-Week Change 3-48.12%
S&P500 52-Week Change 33.55%
52 Week High 390.98
52 Week Low 337.44
50-Day Moving Average 354.23
200-Day Moving Average 361.26

Share Statistics

Avg Vol (3 month) 3501.91k
Avg Vol (10 day) 31.08M
Shares Outstanding 557.69M
Float 54.32M
% Held by Insiders 15.92%
% Held by Institutions 192.97%
Shares Short (Aug 15, 2019) 46.59M
Short Ratio (Aug 15, 2019) 414.91
Short % of Float (Aug 15, 2019) 415.62%
Short % of Shares Outstanding (Aug 15, 2019) 411.42%
Shares Short (prior month Jul 15, 2019) 46.18M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 23/1
Last Split Date 3Jan 17, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-556.79%

Management Effectiveness

Return on Assets (ttm)-27.74%
Return on Equity (ttm)-48.70%

Income Statement

Revenue (ttm)70.34M
Revenue Per Share (ttm)1.33
Quarterly Revenue Growth (yoy)88.80%
Gross Profit (ttm)-243.65M
EBITDA -380.15M
Net Income Avi to Common (ttm)-371.06M
Diluted EPS (ttm)-7.01
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)618.29M
Total Cash Per Share (mrq)10.72
Total Debt (mrq)39.97M
Total Debt/Equity (mrq)4.88
Current Ratio (mrq)9.32
Book Value Per Share (mrq)14.22

Cash Flow Statement

Operating Cash Flow (ttm)-309.85M
Levered Free Cash Flow (ttm)-181.2M